These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 15934495)
61. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Hotton KM; Khorsand M; Hank JA; Albertini M; Kim KM; Wilding G; Salamat MS; Larson M; Sondel P; Schiller JH Cancer; 2000 Apr; 88(8):1892-901. PubMed ID: 10760767 [TBL] [Abstract][Full Text] [Related]
62. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. Boasberg PD; Hoon DS; Piro LD; Martin MA; Fujimoto A; Kristedja TS; Bhachu S; Ye X; Deck RR; O'Day SJ J Invest Dermatol; 2006 Dec; 126(12):2658-63. PubMed ID: 16946711 [TBL] [Abstract][Full Text] [Related]
63. Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. Gitlitz BJ; Figlin RA; Kiertscher SM; Moldawer N; Rosen F; Roth MD J Immunother; 2003; 26(2):171-8. PubMed ID: 12616109 [TBL] [Abstract][Full Text] [Related]
64. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Si Z; Hersey P; Coates AS Melanoma Res; 1996 Jun; 6(3):247-55. PubMed ID: 8819128 [TBL] [Abstract][Full Text] [Related]
65. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161 [TBL] [Abstract][Full Text] [Related]
66. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946 [TBL] [Abstract][Full Text] [Related]
67. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721 [TBL] [Abstract][Full Text] [Related]
68. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875 [TBL] [Abstract][Full Text] [Related]
69. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. Aris M; Bravo AI; Garcia Alvarez HM; Carri I; Podaza E; Blanco PA; Rotondaro C; Bentivegna S; Nielsen M; Barrio MM; Mordoh J Front Immunol; 2019; 10():2213. PubMed ID: 31620131 [TBL] [Abstract][Full Text] [Related]
75. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Zehntner S; Townsend W; Parkes J; Schmidt C; Down M; Bell J; Mulligan R; O'Rourke M; Ellem K; Thomas R Pathology; 1999 May; 31(2):116-22. PubMed ID: 10399166 [TBL] [Abstract][Full Text] [Related]
76. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773 [TBL] [Abstract][Full Text] [Related]
77. Adjuvant therapy for melanoma: a surgical perspective. Sondak VK; Gonzalez RJ; Kudchadkar R Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961 [TBL] [Abstract][Full Text] [Related]